- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
DiMe and Partners Align on Digital Atopic Dermatitis Endpoint
The Digital Medicine Society (DiMe) releases new set of resources to advance the use of digitally measured nocturnal scratch as a meaningful endpoint for atopic dermatitis (AD).
DiMe's release of a new set of resources to advance the use of digitally measured nocturnal scratch as a meaningful endpoint for atopic dermatitis (AD) was completed with founding project partners AbbVie, the Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis, Pfizer, and UCB, along with project collaborators Advancing Innovation in Dermatology, Almirall, Eli Lilly, GSK, Leo Pharma, and Sanofi. In just nine months, the collaboration conducted a mixed-methods study, a comprehensive literature review, a series of workshops, a series of focus groups with payers, and convened a meeting with regulators - all of which informed the development of these open-access resources.
Read the full press release.
